CHR Velocity as a predictor of early molecular response in patients with chronic myeloid leukemia.

被引：1
|
作者：
Malhotra, Pankaj
Chikkodi, Santosh V.
Naseem, Shano
Khadwal, Alka
Prakash, Gaurav
Kumari, Savita
Suri, Vikas
Varma, Neelam
Varma, Subhash
机构：
[1] PGIMER, Chandigarh, India
[2] Nehru Hosp, Chandigarh, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e18038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18038
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Accelerated and blastic phase of chronic myeloid leukemia.
    Dutcher J.P.
    Wiernik P.H.
    Current Treatment Options in Oncology, 2000, 1 (1) : 51 - 62
  • [42] Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
    B Hanfstein
    V Shlyakhto
    M Lauseker
    R Hehlmann
    S Saussele
    C Dietz
    P Erben
    A Fabarius
    U Proetel
    S Schnittger
    S W Krause
    J Schubert
    H Einsele
    M Hänel
    J Dengler
    C Falge
    L Kanz
    A Neubauer
    M Kneba
    F Stegelmann
    M Pfreundschuh
    C F Waller
    K Spiekermann
    G M Baerlocher
    M Pfirrmann
    J Hasford
    W-K Hofmann
    A Hochhaus
    M C Müller
    Leukemia, 2014, 28 : 1988 - 1992
  • [43] High blood viscosity syndrome in patients with chronic myeloid and lymphoid leukemia.
    Golovskoy, BV
    Baev, VM
    Yudina, ON
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 1997, 42 (06): : 10 - 12
  • [44] Expression of circadian genes in chronic myeloid leukemia.
    Sheng-Fung, L
    Yang, MY
    Chang, JG
    Liu, TC
    Chen, TP
    BLOOD, 2003, 102 (11) : 583A - 583A
  • [45] Telomerase activity and progression of chronic myeloid leukemia.
    Li, G
    Song, YH
    Bi, FY
    Ma, XT
    Qian, LS
    Wu, KF
    EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 757 - 757
  • [46] Summary of interferon trials in chronic myeloid leukemia.
    Reiffers, J
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 513 - 513
  • [47] Efficacy and safety of imatinib treatment in elederly patients with chronic myeloid leukemia.
    Martino, B
    Vincelli, L
    Ronco, F
    Modafferi, B
    Princi, D
    Morabito, F
    Izzo, B
    Pane, F
    Nobile, F
    BLOOD, 2004, 104 (11) : 254B - 254B
  • [48] Differential diagnosis of atypical chronic myeloid leukemia.
    dOnofrio, G
    Zini, G
    Tommasi, M
    Salutari, P
    Sica, S
    Leone, G
    BLOOD, 1995, 86 (10) : 3162 - 3162
  • [49] Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia.
    Deininger, Michael W. N.
    Cortes, Jorge E.
    Kim, Dong-Wook
    Nicolini, Franck E.
    Talpaz, Moshe
    Baccarani, Michele
    Mueller, Martin C.
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Guilhot, Francois
    Hochhaus, Andreas
    Goldman, John M.
    Shah, Neil P.
    Kantarjian, Hagop M.
    Hughes, Timothy P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Molecular Predictors for the Response to Nilotinib Treatment After Acquired Imatinib Failure In Ph plus Chronic Myeloid Leukemia.
    Agrawal, Mridul
    Erben, Philipp
    Hanfstein, Benjamin
    Leitner, Armin
    Reynolds, John
    Woodman, Richard C.
    Robin, Laura
    Hofmann, Wolf-Karsten
    Hochhaus, Andreas
    Mueller, Martin C.
    BLOOD, 2010, 116 (21) : 940 - 941
12345